Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit by Mascarella, M., Olonisakin, T., Rumde, P., Vendra, V., Nance, M., Kim, S., Kubik, M., Sridharan, S., Ferris, R., Moon, F., Clayburgh, D., Ohr, J., Joyce, S., Sen, M., Herman, J., Grandis, J., Zandberg, D., Duvvuri, U.

Get full text

TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer by Kumar, Vinod, Yochum, Zachary A., Devadassan, Princey, Huang, Eric H.-B., Miller, Ethan, Baruwal, Roja, Rumde, Purva H., GaitherDavis, Autumn L., Stabile, Laura P., Burns, Timothy F.

Get full text

Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit by Mascarella, Marco A, Olonisakin, Tolani F, Rumde, Purva, Vendra, Varun, Nance, Melonie A, Kim, Seungwon, Kubik, Mark W, Sridharan, Shaum S, Ferris, Robert L, Fenton, Moon J, Clayburgh, Daniel R, Ohr, James P, Joyce, Sonali C, Sen, Malabika, Herman, James G, Grandis, Jennifer R, Zandberg, Dan P, Duvvuri, Umamaheswar

Get full text

Abstract 3853: The TWIST1-p27 signaling pathway is a critical determinant of MET TKI cell cycle arrest and resistance in MET altered non-small cell lung cancer by Kumar, Vinod, Yochum, Zachary A., Devadassan, Princey, Huang, Eric, Miller, Ethan, Ayyala, Vasavi, Rumde, Purva H., Baruwal, Roja, O’Brien, James, Stabile, Laura P., Burns, Timothy F.

Get full text

Abstract 1091: TWIST1 inhibition overcomes resistance to tyrosine kinase inhibitors in MET driven non-small cell lung cancer by Kumar, Vinod, Yochum, Zachary A., Devadassan, Princey, Huang, Eric, Miller, Ethan, Ayyala, Vasavi, Stabile, Laura P., Burns, Timothy F., Rumde, Purva H.

Get full text